{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:47:12Z","timestamp":1790923632556,"version":"4.1.0"},"reference-count":226,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018556","name":"Voyager Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","award":["95,212"],"award-info":[{"award-number":["95,212"]}],"id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","award":["CYP46A1"],"award-info":[{"award-number":["CYP46A1"]}],"id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.neurot.2024.e00434","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T16:09:30Z","timestamp":1724688570000},"page":"e00434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Neurosurgical gene therapy for central nervous system diseases"],"prefix":"10.1016","volume":"21","author":[{"given":"Ruchit V.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Mark","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00434_bib1","first-page":"359","article-title":"Gene therapy comes of age","volume":"2018","author":"Dunbar","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.neurot.2024.e00434_bib2","doi-asserted-by":"crossref","first-page":"12744","DOI":"10.1073\/pnas.94.24.12744","article-title":"Gene therapy","volume":"94","author":"Kay","year":"1997","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurot.2024.e00434_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0168-9525(94)90258-5","article-title":"Gene therapy for neurological disorders","volume":"10","author":"Friedmann","year":"1994","journal-title":"Trends Genet"},{"key":"10.1016\/j.neurot.2024.e00434_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","article-title":"Progress in gene therapy for neurological disorders","volume":"9","author":"Simonato","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2024.e00434_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/2277-9175.98152","article-title":"Viral and nonviral delivery systems for gene delivery","volume":"1","author":"Nayerossadat","year":"2012","journal-title":"Adv Biomed Res"},{"key":"10.1016\/j.neurot.2024.e00434_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.neurot.2024.e00434_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0167-7799(97)01137-2","article-title":"Viral vectors for gene therapy","volume":"16","author":"Robbins","year":"1998","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00434_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1535676019899502","article-title":"Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges","volume":"25","author":"Ghosh","year":"2020","journal-title":"Appl Biosafety"},{"key":"10.1016\/j.neurot.2024.e00434_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2022","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00434_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev.bioeng.10.061807.160514","article-title":"Molecular engineering of viral gene delivery vehicles","volume":"10","author":"Schaffer","year":"2008","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.neurot.2024.e00434_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.neurot.2024.e00434_bib15","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector\u2013mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/mt.2013.281","article-title":"Parkinson\u2019s disease gene therapy: success by design meets failure by efficacy","volume":"22","author":"Bartus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/v11020102","article-title":"Adeno-associated virus (AAV) versus immune response","volume":"11","author":"Rabinowitz","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.neurot.2024.e00434_bib19","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2024.e00434_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/mt.2015.187","article-title":"Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector","volume":"24","author":"Grieger","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","article-title":"Gene therapy for neurodegenerative diseases","volume":"16","author":"Sudhakar","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2024.e00434_bib24","doi-asserted-by":"crossref","first-page":"27053","DOI":"10.1073\/pnas.1910061116","article-title":"A\u00a0systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism","volume":"116","author":"Davidsson","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurot.2024.e00434_bib25","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting \u03b1-synuclein prevents neurodegeneration in a Parkinson\u2019s disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00434_bib26","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/jnnp-2020-322904","article-title":"Data-driven evolution of neurosurgical gene therapy delivery in Parkinson\u2019s disease","volume":"91","author":"Richardson","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2024.e00434_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/hum.2011.162","article-title":"Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum","volume":"23","author":"San Sebastian","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2024.e00434_bib29","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib30","first-page":"1751","article-title":"Direct convective delivery of adeno-associated virus gene therapy for treatment of neurological disorders","volume":"134","author":"Lonser","year":"2021","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.neurot.2024.e00434_bib31","article-title":"Intracerebral lentiviral ABCD1 gene therapy in an early disease onset ALD mouse model","author":"Gong","year":"2022","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/humc.2014.139","article-title":"Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates","volume":"26","author":"Zerah","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/hgtb.2012.120","article-title":"Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis","volume":"23","author":"Sondhi","year":"2012","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.neurot.2024.e00434_bib34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.omtm.2019.12.001","article-title":"AAVrh10 vector corrects disease pathology in MPS IIIA mice and achieves widespread distribution of SGSH in large animal brains","volume":"17","author":"Hocquemiller","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nurt.2007.10.064","article-title":"Image-guided convection-enhanced delivery platform in the treatment of neurological diseases","volume":"5","author":"Fiandaca","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2024.e00434_bib36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib37","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2011.11","article-title":"Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson\u2019s disease","volume":"19","author":"Richardson","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib38","first-page":"560","article-title":"Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles","volume":"107","author":"Szerlip","year":"2007","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.neurot.2024.e00434_bib39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41434-018-0010-2","article-title":"MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates","volume":"25","author":"Nagahara","year":"2018","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib40","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Bobo","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurot.2024.e00434_bib41","first-page":"923","article-title":"Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents","volume":"103","author":"Krauze","year":"2005","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.neurot.2024.e00434_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000323544","article-title":"Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain","volume":"89","author":"Richardson","year":"2011","journal-title":"Stereotact Funct Neurosurg"},{"key":"10.1016\/j.neurot.2024.e00434_bib43","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/mt.2010.114","article-title":"Real-time MR imaging with gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors","volume":"18","author":"Su","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2018.12.001","article-title":"Kinetics and MR-based monitoring of AAV9 vector delivery into cerebrospinal fluid of nonhuman primates","volume":"13","author":"Ohno","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib45","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","article-title":"A\u00a0safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna","volume":"28","author":"Taghian","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib46","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtm.2021.01.009","article-title":"Preclinical biodistribution, tropism, and efficacy of oligotropic AAV\/Olig001 in a mouse model of congenital white matter disease","volume":"20","author":"Francis","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib47","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/acn3.51165","article-title":"Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations","volume":"7","author":"Hinderer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/hum.2021.245","article-title":"Efficacy and safety of a Krabbe disease gene therapy","volume":"33","author":"Hordeaux","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib49","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/hmg\/ddz317","article-title":"Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes","volume":"29","author":"Massaro","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00434_bib50","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2016.184","article-title":"Prevention of neurocognitive deficiency in mucopolysaccharidosis type II mice by central nervous system\u2013directed, AAV9-mediated iduronate sulfatase gene transfer","volume":"28","author":"Laoharawee","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib51","first-page":"754","article-title":"Adenovirus-associated Defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science (1979)"},{"key":"10.1016\/j.neurot.2024.e00434_bib52","first-page":"442","article-title":"Adeno-associated virus vector integration","volume":"11","author":"Deyle","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib53","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1073\/pnas.87.6.2211","article-title":"Site-specific integration by adeno-associated virus","volume":"87","author":"Kotin","year":"1990","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurot.2024.e00434_bib54","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1002\/j.1460-2075.1991.tb04964.x","article-title":"Targeted integration of adeno-associated virus (AAV) into human chromosome 19","volume":"10","author":"Samulski","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.neurot.2024.e00434_bib55","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1073\/pnas.080079397","article-title":"Adeno-associated virus site-specifically integrates into a muscle-specific DNA region","volume":"97","author":"Dutheil","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurot.2024.e00434_bib56","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/brain\/awaa020","article-title":"Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson\u2019s disease","volume":"143","author":"Chu","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00434_bib57","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib58","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1128\/JVI.74.18.8732-8739.2000","article-title":"Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A\/D junction element","volume":"74","author":"Haberman","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib59","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1128\/JVI.03371-13","article-title":"Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans","volume":"88","author":"Mietzsch","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib60","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1128\/jvi.1.5.980-987.1967","article-title":"Physicochemical characterization of adeno-associated satellite virus type 4 and its nucleic acid","volume":"1","author":"Parks","year":"1967","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib61","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1128\/jvi.71.9.6823-6833.1997","article-title":"Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles","volume":"71","author":"Chiorini","year":"1997","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib62","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1099\/0022-1317-81-8-2077","article-title":"Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors","volume":"81","author":"Handa","year":"2000","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib63","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib64","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.neurot.2024.e00434_bib65","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2024.e00434_bib66","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00434_bib68","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1128\/iai.7.6.973-980.1973","article-title":"Isolation and characterization of an avian adenovirus-associated virus","volume":"7","author":"Yates","year":"1973","journal-title":"Infect Immun"},{"key":"10.1016\/j.neurot.2024.e00434_bib69","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.virol.2006.05.023","article-title":"Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5","volume":"353","author":"Lochrie","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.neurot.2024.e00434_bib70","doi-asserted-by":"crossref","first-page":"15238","DOI":"10.1128\/JVI.79.24.15238-15245.2005","article-title":"Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties","volume":"79","author":"Arbetman","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF01348034","article-title":"Isolation of an adeno associated virus from sheep","volume":"60","author":"Clarke","year":"1979","journal-title":"Arch Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib72","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/gt.2009.82","article-title":"Isolation and evaluation of novel adeno-associated virus sequences from porcine tissues","volume":"16","author":"Bello","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib73","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1128\/JVI.02497-09","article-title":"Host range, prevalence, and genetic diversity of adenoviruses in bats","volume":"84","author":"Li","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib74","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1099\/vir.0.19616-0","article-title":"A\u00a0parvovirus isolated from royal python (Python regius) is a member of the genus Dependovirus","volume":"85","author":"Farkas","year":"2004","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib75","first-page":"907","article-title":"Isolation and characterization of adeno-associated viruses from bovine adenovirus types 1 and 2","volume":"37","author":"Myrup","year":"1976","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.neurot.2024.e00434_bib76","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1038\/srep06644","article-title":"Novel adeno-associated viruses derived from pig tissues transduce most major organs in mice","volume":"4","author":"Bello","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00434_bib77","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/mt.2009.216","article-title":"Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates","volume":"18","author":"Dodiya","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib78","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1128\/JVI.75.13.6199-6203.2001","article-title":"Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer","volume":"75","author":"Hildinger","year":"2001","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib79","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","article-title":"Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system","volume":"10","author":"Burger","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib80","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/gt.2012.20","article-title":"Directed evolution of novel adeno-associated viruses for therapeutic gene delivery","volume":"19","author":"Bartel","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib81","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/gt.2016.62","article-title":"Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism","volume":"23","author":"Powell","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib82","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41587-020-00793-4","article-title":"Deep diversification of an AAV capsid protein by machine learning","volume":"39","author":"Bryant","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00434_bib83","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib84","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/brain\/awab182","article-title":"Engineered microRNA-based regulatory element permits safe high-dose mini MECP2 gene therapy in Rett mice","volume":"144","author":"Sinnett","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00434_bib85","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models","volume":"13","author":"Spronck","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hgtb.2015.140","article-title":"Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids","volume":"27","author":"Chamberlain","year":"2016","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.neurot.2024.e00434_bib87","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.neuron.2016.09.021","article-title":"A\u00a0designer AAV variant permits efficient retrograde access to projection neurons","volume":"92","author":"Tervo","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00434_bib88","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib89","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/gt.2012.27","article-title":"Axonal transport of adeno-associated viral vectors is serotype-dependent","volume":"20","author":"Salegio","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2019.00093","article-title":"Adeno-associated virus technologies and methods for targeted neuronal manipulation","volume":"13","author":"Haery","year":"2019","journal-title":"Front Neuroanat"},{"key":"10.1016\/j.neurot.2024.e00434_bib91","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.neuron.2016.09.021","article-title":"A\u00a0designer AAV variant permits efficient retrograde access to projection neurons","volume":"92","author":"Tervo","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00434_bib92","doi-asserted-by":"crossref","first-page":"27053","DOI":"10.1073\/pnas.1910061116","article-title":"A\u00a0systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism","volume":"116","author":"Davidsson","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurot.2024.e00434_bib93","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/hum.2012.015","article-title":"Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice","volume":"23","author":"Piguet","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib94","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/jgm.1449","article-title":"Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat","volume":"12","author":"Fitzsimons","year":"2010","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib95","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib96","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.gt.3302549","article-title":"AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL","volume":"12","author":"Sondhi","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib97","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.mt.6300049","article-title":"Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector","volume":"15","author":"Sondhi","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib98","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/hum.2008.137","article-title":"Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys","volume":"20","author":"Johnston","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib99","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.23442","article-title":"Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson\u2019s disease and nonhuman primate brains","volume":"26","author":"Bartus","year":"2011","journal-title":"Move Disord"},{"key":"10.1016\/j.neurot.2024.e00434_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neuron.2016.11.045","article-title":"AAV-mediated anterograde transsynaptic tagging: mapping corticocollicular input-defined neural pathways for defense behaviors","volume":"93","author":"Zingg","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00434_bib101","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1523\/JNEUROSCI.2158-19.2020","article-title":"Synaptic specificity and application of anterograde transsynaptic AAV for probing neural circuitry","volume":"40","author":"Zingg","year":"2020","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00434_bib102","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neuron.2020.07.010","article-title":"Viral vectors for neural circuit mapping and recent advances in trans-synaptic anterograde tracers","volume":"107","author":"Xu","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00434_bib103","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00434_bib104","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jnc.13861","article-title":"Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells","volume":"140","author":"Merkel","year":"2017","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00434_bib105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and prospects: immune responses to viral vectors","volume":"17","author":"Nayak","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.neurot.2024.e00434_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674021","article-title":"Overcoming immunological challenges limiting capsid-mediated gene therapy with machine learning","volume":"12","author":"Wec","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2024.e00434_bib108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.omtm.2018.09.003","article-title":"Adeno-associated virus neutralizing antibodies in large animals and their impact on brain intraparenchymal gene transfer","volume":"11","author":"Wang","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib109","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","article-title":"Immune response mechanisms against AAV vectors in animal models","volume":"17","author":"Martino","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.655478","article-title":"Cell-mediated immunity to NAGLU transgene following intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome","volume":"12","author":"Gougeon","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2024.e00434_bib111","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1089\/104303401753153947","article-title":"Systematic determination of the packaging limit of lentiviral vectors","volume":"12","author":"Kumar","year":"2001","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib112","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/sj.gt.3301893","article-title":"Lentiviruses in gene therapy clinical research","volume":"9","author":"Connolly","year":"2002","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib113","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1357-4310(97)01106-4","article-title":"The use of herpes simplex virus-based vectors for gene delivery to the nervous system","volume":"3","author":"Lachmann","year":"1997","journal-title":"Mol Med Today"},{"key":"10.1016\/j.neurot.2024.e00434_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-0556-7-1","article-title":"Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer","volume":"7","author":"Federici","year":"2009","journal-title":"Genet Vaccines Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis"},{"key":"10.1016\/j.neurot.2024.e00434_bib116","first-page":"415","article-title":"LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science (1979)"},{"key":"10.1016\/j.neurot.2024.e00434_bib117","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nbt0303-217","article-title":"US authorities uphold suspension of SCID gene therapy","volume":"21","author":"Fox","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00434_bib118","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ymthe.2005.11.012","article-title":"Lentiviral vectors for use in the central nervous system","volume":"13","author":"Jakobsson","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib119","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00434_bib120","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib121","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A\u00a0third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00434_bib122","series-title":"Cell and tissue gene targeting with lentiviral vectors","first-page":"29","author":"Escors","year":"2012"},{"key":"10.1016\/j.neurot.2024.e00434_bib123","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1357-4310(97)01106-4","article-title":"The use of herpes simplex virus-based vectors for gene delivery to the nervous system","volume":"3","author":"Lachmann","year":"1997","journal-title":"Mol Med Today"},{"key":"10.1016\/j.neurot.2024.e00434_bib124","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib125","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib126","doi-asserted-by":"crossref","first-page":"489","DOI":"10.15252\/emmm.201505850","article-title":"Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affected non-human primates by intracerebral lentiviral gene therapy","volume":"8","author":"Meneghini","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib127","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000130","article-title":"Dopamine gene therapy for Parkinson\u2019s disease in a nonhuman primate without associated dyskinesia","volume":"1","author":"Jarraya","year":"2009","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib128","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.omtm.2019.07.002","article-title":"Gene therapy for Parkinson\u2019s disease: preclinical evaluation of optimally configured TH:CH1 fusion for maximal dopamine synthesis","volume":"14","author":"Badin","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib130","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.neurot.2024.e00434_bib131","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib132","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm.1912","article-title":"Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer\u2019s disease","volume":"15","author":"Nagahara","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib133","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1523\/JNEUROSCI.15-04-02819.1995","article-title":"Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration","volume":"15","author":"Chen","year":"1995","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00434_bib134","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.expneurol.2008.03.004","article-title":"Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons","volume":"211","author":"Bishop","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib135","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","article-title":"A\u00a0phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer\u2019s disease","volume":"10","author":"Rafii","year":"2014","journal-title":"Alzheimer\u2019s Demen"},{"key":"10.1016\/j.neurot.2024.e00434_bib136","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-associated viral vector (serotype 2)\u2013nerve growth factor for patients with alzheimer disease","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib137","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/hum.2019.367","article-title":"Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer\u2019s disease identifies a need for improved vector delivery","volume":"31","author":"Castle","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib138","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/exnr.2000.7408","article-title":"Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach","volume":"164","author":"Bankiewicz","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib139","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ymthe.2006.05.005","article-title":"Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC","volume":"14","author":"Bankiewicz","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.wnr.0000198952.38563.05","article-title":"Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys","volume":"17","author":"Daadi","year":"2006","journal-title":"Neuroreport"},{"key":"10.1016\/j.neurot.2024.e00434_bib141","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ymthe.2006.04.008","article-title":"A\u00a0dose-ranging study of AAV-hAADC therapy in parkinsonian monkeys","volume":"14","author":"Forsayeth","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib142","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson disease","volume":"70","author":"Eberling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00434_bib143","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00434_bib144","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A\u00a0phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease","volume":"18","author":"Muramatsu","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib145","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.25450","article-title":"Magnetic resonance imaging\u2013guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease","volume":"85","author":"Christine","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib146","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","article-title":"Safety of AADC gene therapy for moderately advanced Parkinson disease","volume":"98","author":"Christine","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00434_bib147","first-page":"S1","article-title":"AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson\u2019s disease","volume":"35","author":"Factor","year":"2020","journal-title":"Move Disord"},{"key":"10.1016\/j.neurot.2024.e00434_bib148","series-title":"Voyager therapeutics provides update on NBIb-1817 (VY-AADC) gene therapy program","year":"2021"},{"key":"10.1016\/j.neurot.2024.e00434_bib149","first-page":"425","article-title":"Subthalamic GAD gene therapy in a Parkinson\u2019s disease rat model","volume":"298","author":"Luo","year":"2002","journal-title":"Science (1979)"},{"key":"10.1016\/j.neurot.2024.e00434_bib150","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.gt.3302520","article-title":"Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models","volume":"12","author":"Lee","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib151","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.neurot.2024.e00434_bib152","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib153","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90133","article-title":"Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease","volume":"2","author":"Niethammer","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.neurot.2024.e00434_bib154","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.jcbfm.9600364","article-title":"Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism","volume":"27","author":"Emborg","year":"2007","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.neurot.2024.e00434_bib155","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1523\/JNEUROSCI.22-23-10302.2002","volume":"22","author":"Azzouz","year":"2002","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00434_bib156","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000130","article-title":"Dopamine gene therapy for Parkinson\u2019s disease in a nonhuman primate without associated dyskinesia","volume":"1","author":"Jarraya","year":"2009","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib157","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/humc.2018.081","article-title":"Long-term follow-up of a phase I\/II study of ProSavin, a lentiviral vector gene therapy for Parkinson\u2019s disease","volume":"29","author":"Palfi","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib158","first-page":"S173","article-title":"An update on gene therapy approaches for Parkinson\u2019s disease: restoration of dopaminergic function","volume":"11","author":"Van Laar","year":"2021","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.neurot.2024.e00434_bib159","series-title":"Axovant announces positive 12-month data on AXO-lenti-PD and provides updates across gene therapy pipeline programs","year":"2020"},{"key":"10.1016\/j.neurot.2024.e00434_bib160","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","article-title":"Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys","volume":"60","author":"Kordower","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib161","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.mt.6300010","article-title":"Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson\u2019s disease","volume":"15","author":"Gasmi","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib162","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2008.170","article-title":"Transgene expression, bioactivity, and safety of CERE-120 (AAV2-Neurturin) following delivery to the monkey striatum","volume":"16","author":"Herzog","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib163","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/mds.21503","article-title":"Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys","volume":"22","author":"Herzog","year":"2007","journal-title":"Move Disord"},{"key":"10.1016\/j.neurot.2024.e00434_bib164","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2\u2013neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib165","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib166","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.24436","article-title":"Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial","volume":"78","author":"Warren Olanow","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib167","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/hum.2008.201","article-title":"Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys","volume":"20","author":"Eberling","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib168","doi-asserted-by":"crossref","first-page":"9567","DOI":"10.1523\/JNEUROSCI.0942-10.2010","article-title":"Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF","volume":"30","author":"Kells","year":"2010","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00434_bib169","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/mds.27724","article-title":"Trial of magnetic resonance\u2013guided putaminal gene therapy for advanced Parkinson\u2019s disease","volume":"34","author":"Heiss","year":"2019","journal-title":"Move Disord"},{"key":"10.1016\/j.neurot.2024.e00434_bib170","series-title":"AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson\u2019s disease meets primary endpoint","year":"2024"},{"key":"10.1016\/j.neurot.2024.e00434_bib171","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency","volume":"4","author":"Hwu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib172","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","article-title":"Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial","volume":"1","author":"Chien","year":"2017","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.neurot.2024.e00434_bib173","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib174","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/brain\/awy331","article-title":"Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency","volume":"142","author":"Kojima","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00434_bib175","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons","volume":"12","author":"Pearson","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00434_bib176","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib177","doi-asserted-by":"crossref","DOI":"10.1002\/alz.043614","article-title":"PR001 gene therapy improved phenotypes in models of Parkinson\u2019s disease with GBA1 mutation","volume":"16","author":"Sheehan","year":"2020","journal-title":"Alzheimer\u2019s Demen"},{"key":"10.1016\/j.neurot.2024.e00434_bib178","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1089\/hum.2018.206","article-title":"A\u00a0single injection of an optimized adeno-associated viral vector into cerebrospinal fluid corrects neurological disease in a murine model of GM1 gangliosidosis","volume":"31","author":"Hinderer","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib179","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.omtm.2022.10.004","article-title":"AAVrh10 vector corrects pathology in animal models of GM1 gangliosidosis and achieves widespread distribution in the CNS of nonhuman primates","volume":"27","author":"Hocquemiller","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib180","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1089\/hum.2017.163","article-title":"Adeno-associated virus gene therapy in a sheep model of tay\u2013sachs disease","volume":"29","author":"Gray-Edwards","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib181","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/hum.2016.109","article-title":"Direct intracranial injection of AAVrh8 encoding monkey \u03b2-N-acetylhexosaminidase causes neurotoxicity in the primate brain","volume":"28","author":"Golebiowski","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib182","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/mt.2012.153","article-title":"Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease","volume":"20","author":"Rafi","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib183","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/humc.2013.239","article-title":"Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates","volume":"25","author":"Rosenberg","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib184","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/hum.2020.269","article-title":"Safety of direct intraparenchymal AAVrh.10-mediated central nervous system gene therapy for metachromatic leukodystrophy","volume":"32","author":"Rosenberg","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib185","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/hmg\/ddq099","article-title":"Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models","volume":"19","author":"Lattanzi","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00434_bib186","series-title":"Discontinued GM1 gangliosidosis gene therapy shows no evidence of clinical benefit","year":"2024"},{"key":"10.1016\/j.neurot.2024.e00434_bib187","series-title":"Passage bio announces promising interim clinical data from first eight patients with GM1 gangliosidosis in IMAGINE-1 study","author":"Bio","year":"2023"},{"key":"10.1016\/j.neurot.2024.e00434_bib188","series-title":"Signs of trouble emerge as sio gene halts UMass gangliosidosis deal","year":"2022"},{"key":"10.1016\/j.neurot.2024.e00434_bib189","series-title":"Sio gene therapies, Inc. to file for dissolution and declare an initial liquidating distribution of $0.435 per share","year":"2024"},{"key":"10.1016\/j.neurot.2024.e00434_bib190","series-title":"Passage bio reports third quarter 2022 financial results and provides business updates","author":"Bio","year":"2022"},{"key":"10.1016\/j.neurot.2024.e00434_bib191","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.ymgme.2017.12.352","article-title":"Intracerebral gene therapy in children with metachromatic leukodystrophy: results of a phase I\/II trial","volume":"123","author":"Sevin","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.neurot.2024.e00434_bib192","article-title":"Intravenous delivery for treatment of mucopolysaccharidosis type I: a comparison of AAV serotypes 9 and rh10","volume":"24","author":"Belur","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.neurot.2024.e00434_bib193","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.618360","article-title":"Comparative effectiveness of intracerebroventricular, intrathecal, and intranasal routes of AAV9 vector administration for genetic therapy of neurologic disease in murine mucopolysaccharidosis type I","volume":"14","author":"Belur","year":"2021","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2024.e00434_bib194","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/hum.2015.170","article-title":"A\u00a0preclinical study evaluating AAVrh10-based gene therapy for sanfilippo syndrome","volume":"27","author":"Winner","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib195","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1089\/hum.2018.189","article-title":"An improved adeno-associated virus vector for neurological correction of the mouse model of mucopolysaccharidosis IIIA","volume":"30","author":"Gray","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib196","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, efficient, and reproducible gene therapy of the brain in the dog models of sanfilippo and hurler syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib197","article-title":"Gene therapies for mucopolysaccharidosis show safety","year":"2022","journal-title":"Efficacy"},{"key":"10.1016\/j.neurot.2024.e00434_bib198","series-title":"Additional positive interim data from phase I\/II\/III CAMPSIITETM trial of REGENXBIO\u2019s RGX-121 for the treatment of MPS II (hunter syndrome) presented at 19th annual WORLDSymposiumTM","year":"2023"},{"key":"10.1016\/j.neurot.2024.e00434_bib199","series-title":"Lysogene gene therapies show promise in GM1 gangliosidosis and MPSIIIA","year":"2022"},{"key":"10.1016\/j.neurot.2024.e00434_bib200","series-title":"MPS type IIIA gene therapy trial fails primary endpoint","year":"2022"},{"key":"10.1016\/j.neurot.2024.e00434_bib201","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2018.07.015","article-title":"Longitudinal in vivo monitoring of the CNS demonstrates the efficacy of gene therapy in a sheep model of CLN5 batten disease","volume":"26","author":"Mitchell","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib202","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib203","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5413","article-title":"Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2","volume":"12","author":"Sondhi","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00434_bib204","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/mt.2013.138","article-title":"A\u00a0single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS gene therapy in canavan mice","volume":"21","author":"Ahmed","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90807","article-title":"Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease","volume":"2","author":"Gessler","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.neurot.2024.e00434_bib206","series-title":"Canavan disease gene therapy BBP-812 shows preliminary efficacy and safety","year":"2023"},{"key":"10.1016\/j.neurot.2024.e00434_bib207","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1093\/hmg\/ddl241","article-title":"Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration","volume":"15","author":"Gass","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00434_bib208","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/acn3.51165","article-title":"Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations","volume":"7","author":"Hinderer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib209","doi-asserted-by":"crossref","DOI":"10.1002\/alz.043632","article-title":"Preclinical development of PR006, a gene therapy for the treatment of frontotemporal dementia with progranulin mutations","volume":"16","author":"Heckman","year":"2020","journal-title":"Alzheimer\u2019s Demen"},{"key":"10.1016\/j.neurot.2024.e00434_bib210","series-title":"Intrathalamic delivery of AVB-101 rescues pathology in progranulin deficient mice and achieves widespread cortical expression in two large animal models","author":"Shaw","year":"2022"},{"key":"10.1016\/j.neurot.2024.e00434_bib211","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/mds.26020","article-title":"Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing","volume":"29","author":"Aronin","year":"2014","journal-title":"Move Disord"},{"key":"10.1016\/j.neurot.2024.e00434_bib212","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib213","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz976","article-title":"Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease","author":"Caron","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.neurot.2024.e00434_bib214","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awv384","article-title":"CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington\u2019s disease","volume":"139","author":"Boussicault","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00434_bib215","series-title":"Gene therapy AMT-130 shows promising results on several outcomes in phase 1\/2 study of Huntington disease","year":"2023"},{"key":"10.1016\/j.neurot.2024.e00434_bib216","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/hum.2022.037","article-title":"Cell-selective adeno-associated virus-mediated SCN1A gene regulation therapy rescues mortality and seizure phenotypes in a Dravet syndrome mouse model and is well tolerated in nonhuman primates","volume":"33","author":"Tanenhaus","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00434_bib217","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1172805","article-title":"Advanced genetic therapies for the treatment of Rett syndrome: state of the art and future perspectives","volume":"17","author":"Palmieri","year":"2023","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurot.2024.e00434_bib218","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omtm.2017.04.007","article-title":"Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome","volume":"5","author":"Gadalla","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib219","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.omtm.2017.04.006","article-title":"Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery","volume":"5","author":"Sinnett","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00434_bib220","series-title":"Neurogene announces expansion and plans for more rapid patient enrollment of Rett syndrome gene therapy clinical trial","year":"2024"},{"key":"10.1016\/j.neurot.2024.e00434_bib221","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.neuroscience.2008.02.066","article-title":"Kainate receptors in epilepsy and excitotoxicity","volume":"158","author":"Vincent","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurot.2024.e00434_bib222","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/j.neubiorev.2013.10.011","article-title":"The kainic acid model of temporal lobe epilepsy","volume":"37","author":"L\u00e9vesque","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.neurot.2024.e00434_bib223","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ana.26723","article-title":"GluK2 is a target for gene therapy in drug-resistant temporal lobe epilepsy","volume":"94","author":"Boileau","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00434_bib224","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000203971","article-title":"Preclinical proof-of-concept of a novel AAV9-microRNA based targeting of GRIK2 for the treatment of temporal lobe epilepsy (S44.001)","volume":"100","author":"Pearson","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00434_bib225","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10545-011-9289-5","article-title":"Diagnosis and management of glutaric aciduria type I \u2013 revised recommendations","volume":"34","author":"K\u00f6lker","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2024.e00434_bib226","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.fmre.2022.08.013","article-title":"Treatment of glutaric aciduria type I (GA-I) via intracerebroventricular delivery of GCDH","volume":"2","author":"Guo","year":"2022","journal-title":"Fundam Res"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792400120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792400120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T21:12:21Z","timestamp":1727125941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792400120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":226,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S187874792400120X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00434","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurosurgical gene therapy for central nervous system diseases","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00434"}}